Literature DB >> 22437436

Levels of amyloid beta-42, interleukin-6 and tumor necrosis factor-alpha in Alzheimer's disease and vascular dementia.

Sema Uslu1, Zubeyde Eken Akarkarasu, Demet Ozbabalik, Serhat Ozkan, Omer Colak, Emine Sutken Demirkan, Ayşe Ozkiris, Canan Demirustu, Ozkan Alatas.   

Abstract

Amyloid β42 (Aβ42) and proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) have been suggested to contribute to the pathogenesis of Alzheimer's disease (AD) and vascular dementia (VaD). Our aim was to examine whether the changes in these parameters would be able to discriminate the patients with AD from those with VaD and from healthy individuals. We have analyzed the levels of Aβ42, IL-6 and TNF-α in the serum of newly diagnosed 28 AD patients, 16 VaD patients and 26 healthy non-demented controls. We also investigated whether there is an association between Aβ42, IL-6 and TNF-α levels and mini-mental state examination (MMSE) scores and body mass indexes (BMI) of patients. Our data showed a significant decrease in serum Aβ-42 levels in AD patients compared to VaD patients and controls. Levels of IL-6 and TNF-α were not different between AD patients, VaD patients and controls. We observed a correlation between Aβ-42 levels and MMSE scores and BMI levels in both AD and VaD patients. However, Aβ-42 levels were not correlated with IL-6 and TNF-α levels. Significantly lower levels of Aβ42 found in the serum of AD patients than that of VaD patients and controls suggests that it can be a specific biochemical marker for AD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22437436     DOI: 10.1007/s11064-012-0750-0

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  39 in total

Review 1.  Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies.

Authors:  K J Anstey; N Cherbuin; M Budge; J Young
Journal:  Obes Rev       Date:  2011-02-23       Impact factor: 9.213

2.  Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease.

Authors:  P Angelis; S Scharf; A Mander; F Vajda; N Christophidis
Journal:  Neurosci Lett       Date:  1998-03-13       Impact factor: 3.046

Review 3.  Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid.

Authors:  C E Teunissen; J de Vente; H W M Steinbusch; C De Bruijn
Journal:  Neurobiol Aging       Date:  2002 Jul-Aug       Impact factor: 4.673

4.  Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease.

Authors:  Antón Alvarez; Ramón Cacabelos; Carolina Sanpedro; Manuel García-Fantini; Manuel Aleixandre
Journal:  Neurobiol Aging       Date:  2006-03-29       Impact factor: 4.673

5.  Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?

Authors:  F Licastro; S Pedrini; L Caputo; G Annoni; L J Davis; C Ferri; V Casadei; L M Grimaldi
Journal:  J Neuroimmunol       Date:  2000-02-01       Impact factor: 3.478

6.  Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate Alzheimer's disease patients.

Authors:  Roberto Paganelli; Angelo Di Iorio; Luca Patricelli; Fausto Ripani; Eleonora Sparvieri; Raffaella Faricelli; Carla Iarlori; Ettore Porreca; Mario Di Gioacchino; Giuseppe Abate
Journal:  Exp Gerontol       Date:  2002 Jan-Mar       Impact factor: 4.032

7.  Increased production of inflammatory cytokines in mild cognitive impairment.

Authors:  Shino Magaki; Claudius Mueller; Cindy Dickson; Wolff Kirsch
Journal:  Exp Gerontol       Date:  2006-11-07       Impact factor: 4.032

8.  Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

Authors:  G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

Review 9.  The role of inflammation in Alzheimer's disease.

Authors:  Ehab E Tuppo; Hugo R Arias
Journal:  Int J Biochem Cell Biol       Date:  2005-02       Impact factor: 5.085

10.  Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study.

Authors:  Johan Sundelöf; Vilmantas Giedraitis; Michael C Irizarry; Johan Sundström; Erik Ingelsson; Elina Rönnemaa; Johan Arnlöv; Malin Degerman Gunnarsson; Bradley T Hyman; Hans Basun; Martin Ingelsson; Lars Lannfelt; Lena Kilander
Journal:  Arch Neurol       Date:  2008-02
View more
  15 in total

1.  Fatty acids rehabilitated long-term neurodegenerative: like symptoms in olfactory bulbectomized rats.

Authors:  Shlomo Yehuda; Sharon Rabinovitz
Journal:  J Neural Transm (Vienna)       Date:  2014-10-08       Impact factor: 3.575

2.  Immune function, cortisol, and cognitive decline & dementia in an aging latino population.

Authors:  Rebecca C Stebbins; Jessie K Edwards; Brenda L Plassman; Y Claire Yang; Grace A Noppert; Mary Haan; Allison E Aiello
Journal:  Psychoneuroendocrinology       Date:  2021-09-15       Impact factor: 4.905

Review 3.  Targeting interleukin-6 for noninfectious uveitis.

Authors:  Phoebe Lin
Journal:  Clin Ophthalmol       Date:  2015-09-11

Review 4.  Neuroinflammation in Alzheimer's disease.

Authors:  Fengjin Zhang; Linlan Jiang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-01-30       Impact factor: 2.570

5.  Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting.

Authors:  Michelle Kokkinou; Lucy C Beishon; Nadja Smailagic; Anna H Noel-Storr; Chris Hyde; Obioha Ukoumunne; Rosemary E Worrall; Anja Hayen; Meera Desai; Abhishekh Hulegar Ashok; Eleanor J Paul; Aikaterini Georgopoulou; Tiziana Casoli; Terry J Quinn; Craig W Ritchie
Journal:  Cochrane Database Syst Rev       Date:  2021-02-10

6.  Compound danshen tablet ameliorated aβ25-35-induced spatial memory impairment in mice via rescuing imbalance between cytokines and neurotrophins.

Authors:  Yan Teng; Meng-Qi Zhang; Wen Wang; Li-Tao Liu; Li-Ming Zhou; Shi-Kun Miao; Li-Hong Wan
Journal:  BMC Complement Altern Med       Date:  2014-01-14       Impact factor: 3.659

7.  Increased basal and alum-induced interleukin-6 levels in geriatric patients are associated with cardiovascular morbidity.

Authors:  Nathalie Compté; Karim Zouaoui Boudjeltia; Michel Vanhaeverbeek; Sandra De Breucker; Thierry Pepersack; Joel Tassignon; Anne Trelcat; Stanislas Goriely
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

8.  Anti-neuroinflammatory effects of the calcium channel blocker nicardipine on microglial cells: implications for neuroprotection.

Authors:  Bor-Ren Huang; Pei-Chun Chang; Wei-Lan Yeh; Chih-Hao Lee; Cheng-Fang Tsai; Chingju Lin; Hsiao-Yun Lin; Yu-Shu Liu; Caren Yu-Ju Wu; Pei-Ying Ko; Shiang-Suo Huang; Horng-Chaung Hsu; Dah-Yuu Lu
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

Review 9.  A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer's disease.

Authors:  Keerthanaa Balasubramanian Shanthi; Sreeram Krishnan; P Rani
Journal:  SAGE Open Med       Date:  2015-08-10

10.  The Protective Effects of Clams on Hypercholesterolemia in Late-Stage Triple-Transgenic Alzheimer's Diseased Mice Hearts.

Authors:  You-Liang Hsieh; Hsu-Ju Teng; Yen-Hung Yeh; Cheng-Hong Hsieh; Chih-Yang Huang
Journal:  Mar Drugs       Date:  2018-08-01       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.